Origin: The APOE2 targeted replacement mouse was developed in the laboratory of Nobuya Maeda at the University of North Carolina. The model was created by targeting the murine Apoe gene for replacement with the human APOE2 allele in E14TG2a ES cells and injecting the targeted cells into blastocysts. Resultant chimeras were backcrossed to C57BL/6 for seven generations (N7). Taconic received stock in 2000. The mice were backcrossed two additional times (N9) and embryo transfer derived. The colony is maintained through incrossing of homozygotes.
Genetics: Wild type for Nnt mutation
Initial Publication: Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse apoe with human APOE*2. J Clin Invest, 102(1):130-5.
Animal Diet: NIH #31M Rodent Diet
Label License: Conditions of Use for Taconic Transgenic Models™
|4 to 8||$305.10||$305.10|
|9 to 12||$312.40||$312.40|
Contact Us or call: